These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 734739)

  • 1. Antigenic properties of lymphoma sublines derived from a drug-treated immunogenic L5178Y leukemia.
    Fioretti MC; Romani L; Taramelli D; Goldin A
    Transplantation; 1978 Dec; 26(6):449-51. PubMed ID: 734739
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytogenetic analysis of an immunogenic mutant of the L5178Y lymphoma.
    Greenberg AH; Manougian J; Ray M; Goldenberg GJ
    Acta Cytol; 1980; 24(3):232-6. PubMed ID: 6773281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-mediated changes of tumour cell immunogenicity and antigenicity.
    Puccetti P; Romani L; Taramelli D; Bonmassar E; Fioretti MC
    Int J Tissue React; 1982; 4(3):189-99. PubMed ID: 6183194
    [No Abstract]   [Full Text] [Related]  

  • 4. Cross-reacting antigens on L5178Y cells which serve as targets for cytotoxic T-lymphocyte lysis during establishment of the tumor dormant state.
    Weinhold KJ; Wheelock EF
    Cancer Res; 1982 Sep; 42(9):3607-16. PubMed ID: 6179603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential antigenic expression of the DBA/2 lymphoma L1210 and its sublines: cross-reactivity with C3H mammary tumors as defined by syngeneic monoclonal antibodies.
    Rapp L; Fuji H
    Cancer Res; 1983 Jun; 43(6):2592-9. PubMed ID: 6342755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-mediated immunogenic changes of virus-induced leukemia in vivo.
    Houchens DP; Bonmassar E; Gaston MR; Kende M; Goldin A
    Cancer Res; 1976 Apr; 36(4):1347-52. PubMed ID: 1260759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosensitivity and histocompatibility antigens in drug-altered leukemic cells.
    Nicolin A; Franco P; Testorelli C; Goldin A
    Cancer Res; 1976 Jan; 36(1):222-7. PubMed ID: 1248001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential tumor immunogenicity of DBA/2 mouse lymphoma L1210 and its sublines. II. Increased expression of tumor-associated antigens on subline cells recognized by serologic and transplantation methods.
    Fuji H; Mihich E; Pressman D
    J Natl Cancer Inst; 1979 Jun; 62(6):1503-10. PubMed ID: 286122
    [No Abstract]   [Full Text] [Related]  

  • 9. Antigenic modulation as a mechanism for tumor escape from immune destruction: identification of modulation-positive and modulation-negative mouse lymphomas with xenoantisera to murine leukemia virus gp70.
    Stackpole CW; Cremona P; Leonard C; Stremmel P
    J Immunol; 1980 Oct; 125(4):1715-23. PubMed ID: 6251136
    [No Abstract]   [Full Text] [Related]  

  • 10. Distribution of Lyb-4.1 and other membrane antigens on murine lymphoid tumors.
    Howe RC; Nelson RS; Rogan KM; Ahmed A; Aiken JJ; Dorf ME; Scherer JC; Sell KW; Humphreys RE
    J Natl Cancer Inst; 1979 Aug; 63(2):375-8. PubMed ID: 313471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes of the immunogenic properties of a radiation-induced mouse lymphoma following treatment with antitumor drugs.
    Bonmassar E; Testorelli C; Franco P; Goldin A; Cudkowicz G
    Cancer Res; 1975 Aug; 35(8):1957-62. PubMed ID: 1149019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Location of tumoral antigens in L5178Y murine lymphoma cells.
    Ramos-Damián ME; Gómez-Estrada H; Hernández-Delgado J; Tapia-Arizmendi L; Feria-Velasco A
    Arch Invest Med (Mex); 1980; 11(3):425-34. PubMed ID: 7469659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined chemoimmunotherapy of L5178Y lymphoma.
    Balázová E; Koza I; Ujházy V
    Neoplasma; 1978; 25(6):653-7. PubMed ID: 752113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Secondary cytotoxic "in vitro" response: crossed antigenic response of murine lymphoma sublines treated with DTIC].
    Romani L; Taramelli D; Fioretti MC
    Boll Soc Ital Biol Sper; 1977 Aug; 53(15):1272-8. PubMed ID: 603675
    [No Abstract]   [Full Text] [Related]  

  • 15. Liposomes as a tool to study the role of membrane presentation in the immunogenicity of a MuLV-related tumor antigen.
    Gerlier D; Bakouche O; Dore JF
    J Immunol; 1983 Jul; 131(1):485-90. PubMed ID: 6190925
    [No Abstract]   [Full Text] [Related]  

  • 16. "In vitro" induction of primary cell-mediated immune response to drug-altered lymphoma cells.
    Romani L; Fioretti MC
    Boll Soc Ital Biol Sper; 1978 Oct; 54(20):1943-9. PubMed ID: 753282
    [No Abstract]   [Full Text] [Related]  

  • 17. Alloreactivity and tumor antigens: generation of syngeneic antilymphoma killer lymphocytes by alloimmunization of mice with normal cells.
    Sensi ML; Parenza M; Parmiani G
    J Natl Cancer Inst; 1983 Feb; 70(2):291-7. PubMed ID: 6571938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies to the L1210 murine leukemia cell line and to a drug-altered subline.
    Testorelli C; Archetti YL; Aresca P; Del Vecchio L
    Cancer Res; 1985 Nov; 45(11 Pt 1):5299-303. PubMed ID: 4053006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-mediated immunity to Friend virus-induced leukemia.
    Ting CC; Shiu G; Rodrigues D; Herberman RB
    Cancer Res; 1974 Jul; 34(7):1684-7. PubMed ID: 4134674
    [No Abstract]   [Full Text] [Related]  

  • 20. Presence of antibody against mouse fetal antigen in the sera from C57BL-6 mice immunized with Rauscher leukemia.
    Ishimoto A; Ito Y
    Cancer Res; 1972 Nov; 32(11):2332-7. PubMed ID: 4343227
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.